Artivion Inc (FRA:CYL)
€ 26.75 0.1 (0.38%) Market Cap: 1.14 Bil Enterprise Value: 1.43 Bil PE Ratio: 0 PB Ratio: 3.89 GF Score: 74/100

CryoLife Inc at Morgan Stanley Healthcare Conference Transcript

Sep 11, 2019 / 03:40PM GMT
Release Date Price: €24.61 (+2.33%)
Unidentified Analyst

(technical difficulty)

So I mean this business has been focused on acceleration in the back half of the year and into 2020 and delivering this kind of high single-digit to double-digit earnings growth rate and JOTEC has been a big part of its story.

Questions & Answers

Unidentified Analyst

You're upgrading over half the portfolio, and I think we're in the process of a few regulatory filings.

Can you just start by giving us an update on where you are in that process?

James Patrick MacKin
CryoLife, Inc. - Chairman, President & CEO

Yes. So there's 3 new stent grafts that we're bringing out. They have been submitted for a regulatory approval. So there's a new thoracic stent graft called E-nya. A new off-the-shelf branched thoracoabdominal device called E-nside. Those are both submitted for CE mark in February and then we've got our third device, which is -- what's called the -- in a Frozen Elephant Trunk category, which is called E-vita Open Neo. That was submitted in early

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot